{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T23:03:26Z","timestamp":1780355006323,"version":"3.54.1"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1097\/iae.0000000000001109","type":"journal-article","created":{"date-parts":[[2016,6,11]],"date-time":"2016-06-11T16:27:24Z","timestamp":1465662444000},"page":"2399-2408","source":"Crossref","is-referenced-by-count":36,"title":["INTRAVITREAL INFLIXIMAB IN REFRACTORY UVEITIS IN BEHCET'S DISEASE"],"prefix":"10.1097","volume":"36","author":[{"given":"Mostafa M.E.","family":"Hamza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamer A.","family":"Macky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Karim","family":"Sidky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaafar","family":"Ragab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud M.","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20-20210130","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1167\/iovs.07-0932","article-title":"A pilot study on ocular safety of intravitreal infliximab in a rabbit model","volume":"49","author":"Giansanti","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R2-20-20210130","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00417-008-0967-4","article-title":"Intravitreal administration of the anti-TNF monoclonal antibody infliximab in the rabbit","volume":"247","author":"Theodossiadis","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R3-20-20210130","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1177\/112067210901900521","article-title":"Intravitreal infliximab in experimental endotoxin-induced uveitis","volume":"19","author":"Hosseini","year":"2009","journal-title":"Eur J Ophthalmol"},{"key":"R4-20-20210130","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1089\/jop.2009.0035","article-title":"Ocular safety of infliximab in rabbit and cell culture models","volume":"26","author":"Giansanti","year":"2010","journal-title":"J Ocul Pharmacol Ther"},{"key":"R5-20-20210130","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1590\/S0004-27492011000500009","article-title":"A safety study of retinal toxicity after serial intravitreal injections of infliximab in rabbits eyes","volume":"74","author":"Rassi","year":"2011","journal-title":"Arq Bras Oftalmol"},{"key":"R6-20-20210130","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1097\/IAE.0b013e3182252a23","article-title":"Toxicity and retinal penetration of infliximab in primates","volume":"32","author":"Melo","year":"2012","journal-title":"Retina"},{"key":"R7-20-20210130","doi-asserted-by":"crossref","first-page":"5328","DOI":"10.1167\/iovs.09-3569","article-title":"Intravitreal infliximab clearance in a rabbit model: different sampling methods and assay techniques","volume":"50","author":"Giansanti","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R8-20-20210130","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.ajo.2008.12.004","article-title":"Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-related macular degeneration","volume":"147","author":"Theodossiadis","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"R9-20-20210130","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/IAE.0b013e3181bcef3b","article-title":"Adverse events after intravitreal infliximab (Remicade)","volume":"30","author":"Giganti","year":"2010","journal-title":"Retina"},{"key":"R10-20-20210130","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1097\/IAE.0b013e3181e9f942","article-title":"Intravitreal infliximab in patients with macular degeneration who are nonresponders to antivascular endothelial growth factor therapy","volume":"30","author":"Arias","year":"2010","journal-title":"Retina"},{"key":"R11-20-20210130","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1097\/IAE.0b013e3181d3758a","article-title":"Intravitreal infliximab for the treatment of sight-threatening chronic noninfectious uveitis","volume":"30","author":"Farvardin","year":"2010","journal-title":"Retina"},{"key":"R12-20-20210130","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1097\/IAE.0b013e3181eac7a6","article-title":"Intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: a pilot study from the Pan-American Collaborative Retina Study Group","volume":"31","author":"Wu","year":"2011","journal-title":"Retina"},{"key":"R13-20-20210130","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s10792-012-9559-8","article-title":"Intravitreal infliximab for refractory pseudophakic cystoid macular edema: results of the Pan-American Collaborative Retina Study Group","volume":"32","author":"Wu","year":"2012","journal-title":"Int Ophthalmol"},{"key":"R14-20-20210130","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1089\/jop.2011.0199","article-title":"Long-term effects of intravitreal infliximab for treatment of sight-threatening chronic noninfectious uveitis","volume":"28","author":"Farvardin","year":"2012","journal-title":"J Ocul Pharmacol Ther"},{"key":"R15-20-20210130","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ajo.2012.03.035","article-title":"Intravitreal infliximab for sight-threatening relapsing uveitis in Beh\u00e7et disease: a pilot study in 15 patients","volume":"154","author":"Markomichelakis","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"R16-20-20210130","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1089\/jop.2012.0203","article-title":"Intravitreal tumor necrosis factor-alpha inhibitors for neovascular age-related macular degeneration suboptimally responsive to antivascular endothelial growth factor agents: a pilot study from the Pan American Collaborative Retina Study Group","volume":"29","author":"Wu","year":"2013","journal-title":"J Ocul Pharmacol Ther"},{"key":"R17-20-20210130","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1177\/039463201302600321","article-title":"Intravitreal infliximab for choroidal neovascularization in patients refractory to conventional treatments","volume":"26","author":"Semeraro","year":"2013","journal-title":"Int J Immunopathol Pharmacol"},{"key":"R18-20-20210130","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1590\/S0004-27492013000300010","article-title":"Intravitreal bevacizumab combined with infliximab in the treatment of choroidal neovascularization secondary to age-related macular degeneration: case report series","volume":"76","author":"Freitas","year":"2013","journal-title":"Arq Bras Oftalmol"},{"key":"R19-20-20210130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/IAE.0b013e3181cde727","article-title":"More questions than answers: a call for a moratorium on the use of intravitreal infliximab outside of a well-designed trial","volume":"30","author":"Pulido","year":"2010","journal-title":"Retina"},{"key":"R20-20-20210130","first-page":"39","article-title":"Anti-tumor necrosis factor alpha for retinal diseases: current knowledge and future concepts","volume":"7","author":"Mirshahi","year":"2012","journal-title":"J Ophthalmic Vis Res"},{"key":"R21-20-20210130","first-page":"1078","article-title":"International Study Group for Behcets disease.","volume":"335","year":"1990","journal-title":"Lancet"},{"key":"R22-20-20210130","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Results of the First International Workshop. Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group.","volume":"140","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"R23-20-20210130","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0161-6420(85)34001-0","article-title":"Standardization of vitreal inflammatory activity in intermediate and posterior uveitis","volume":"92","author":"Nussenblatt","year":"1985","journal-title":"Ophthalmology"},{"key":"R24-20-20210130","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/IAE.0b013e3181b48fb4","article-title":"Infliximab stability after reconstitution, dilution, and storage under refrigeration","volume":"30","author":"Beer","year":"2010","journal-title":"Retina"},{"key":"R25-20-20210130","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1136\/ard.2007.080432","article-title":"EULAR recommendations for the management of Beh\u00e7et disease","volume":"67","author":"Hatemi","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R26-20-20210130","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJM199910213411707","article-title":"Beh\u00e7et's disease","volume":"341","author":"Sakane","year":"1999","journal-title":"New Engl J Med"},{"key":"R27-20-20210130","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0049-0172(98)80001-2","article-title":"Beh\u00e7et's disease","volume":"27","author":"Kaklamani","year":"1998","journal-title":"Semin Arthritis Rheum"},{"key":"R28-20-20210130","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1046\/j.1365-4362.2003.01741.x","article-title":"Evaluation of clinical findings according to sex in 2313 Turkish patients with Beh\u00e7et's disease","volume":"42","author":"Tursen","year":"2003","journal-title":"Int J Dermatol"},{"key":"R29-20-20210130","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/S0002-9394(03)00791-8","article-title":"Childhood-onset uveitis in Beh\u00e7et disease: a descriptive study of 36 cases","volume":"136","author":"Tugal-Tutkun","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"R30-20-20210130","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ajo.2004.03.022","article-title":"Uveitis in Beh\u00e7et disease: an analysis of 880 patients","volume":"138","author":"Tugal-Tutkun","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"R31-20-20210130","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S1726-4901(08)70159-X","article-title":"Behcet's disease with uveitis in Taiwan","volume":"71","author":"Chung","year":"2008","journal-title":"J Chin Med Assoc"},{"key":"R32-20-20210130","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10792-008-9203-9","article-title":"Pattern of uveitis in Beh\u00e7et's disease in a referral center in Tunisia, North Africa","volume":"29","author":"Khairallah","year":"2009","journal-title":"Int Ophthalmol"},{"key":"R33-20-20210130","first-page":"619","article-title":"TNF and TNFR biology in health and disease","volume":"47","author":"McDermott","year":"2001","journal-title":"Cell Mol Biol (noisy-le-grand"},{"key":"R34-20-20210130","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.preteyeres.2008.11.005","article-title":"Therapeutic monoclonal antibodies in ophthalmology","volume":"28","author":"Rodrigues","year":"2009","journal-title":"Prog Retin Eye Res"},{"key":"R35-20-20210130","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/rheumatology\/keh205","article-title":"Biological therapies in the spondyloarthritides\u2014the current state","volume":"43","author":"Braun","year":"2004","journal-title":"Rheumatology"},{"key":"R36-20-20210130","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicenter trial","volume":"359","author":"Braun","year":"2002","journal-title":"Lancet"},{"key":"R37-20-20210130","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.autrev.2004.08.004","article-title":"Potential off-label use of infliximab in autoimmune and non-autoimmune diseases","volume":"4","author":"Atzeni","year":"2005","journal-title":"Autoimmun Rev"},{"key":"R38-20-20210130","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2165\/00063030-200519040-00002","article-title":"Biologics in the treatment of transplant rejection and ischaemia\/reperfusion injury","volume":"19","author":"Pascher","year":"2005","journal-title":"Biodrugs"},{"key":"R39-20-20210130","first-page":"1","article-title":"Treatment of therapy-resistant sarcoidosis with adalimumab","volume":"25","author":"Callejas-Rubio","year":"2005","journal-title":"Clin Rheumatol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000001109","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T01:16:04Z","timestamp":1620954964000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006982-201612000-00020"}},"subtitle":["A Safety and Efficacy Clinical Study"],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000001109","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]}}}